Inside the research
Roivant Sciences Ltd.
ROIV Research profile · latest available data
Price overview
$35.80
▼ -0.33 (-0.9%)
| 52w hi | $41.81 |
|---|---|
| 52w lo | $14.96 |
| Vol | 6.76M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.06
| Short | +0.48 |
|---|---|
| Medium | +0.12 |
| Long | -0.88 |
computed 2026-09-27
Key fundamentals
Roivant Sciences Ltd.
Healthcare · Biotechnology
| Market cap | $25.86B |
|---|---|
| Enterprise value | $22.81B |
| Forward P/E | -20.84x |
| EV / EBITDA | -16.77x |
| P / S (ttm) | 3433.24x |
| Profit margin | 0.0% |
| Return on equity | -8.5% |
| Revenue growth | -33.5% |
| Debt / equity | 2.18 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.27 | |
| Sector | +0.08 | |
| Technical | +0.28 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Risk Metrics
| Beta vs SPX | 0.92 |
|---|---|
| Corr SPX | 0.37 |
| Annual vol | 39.9% |
| Annual ret | +62.5% |
| Sharpe | 1.57 |
| Max DD | -28.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $35.67 |
|---|---|
| High / Low | $41.00 / $29.00 |
| Median | $35.00 |
| Analysts | 12 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 10 | |
| Hold | 1 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-16 | Piper Sandler | → Overweight |
| 2026-03-04 | HC Wainwright & Co. | → Buy |
| 2026-02-10 | HC Wainwright & Co. | → Buy |
| 2026-02-10 | Citigroup | → Buy |
| 2026-02-09 | Guggenheim | → Buy |
| 2025-12-15 | Leerink Partners | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-06 | Earnings Release, Exhibits | read |
| 2026-05-20 | Earnings Release, Exhibits | read |
| 2026-04-02 | Earnings Release, Reg FD Disclosure… | read |
| 2026-03-03 | Material Agreement, Reg FD Disclosure… | read |
| 2026-03-03 | Reg FD Disclosure, Exhibits | read |
| 2026-02-06 | Earnings Release, Exhibits | read |
| 2025-12-11 | Reg FD Disclosure, Exhibits | read |
| 2025-11-10 | Earnings Release, Exhibits | read |
| 2025-09-17 | Reg FD Disclosure, Other Material Event… | read |
| 2025-09-11 | Shareholder Vote, Exhibits | read |
| 2025-09-03 | Reg FD Disclosure, Other Material Event… | read |
| 2025-08-11 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-30 | Gline Matthew | CEO | Withheld for tax | 76.17K | $2.70M |
| 2026-06-30 | Fitzgerald Meghan | Option exercise | 10.00K | $88.00K | |
| 2026-06-30 | Fitzgerald Meghan | Sell | 10.00K | $349.00K | |
| 2026-06-30 | Torti Frank | President and Vant Chair | Withheld for tax | 40.31K | $1.43M |
| 2026-06-30 | Sukhatme Mayukh | President & CIO | Withheld for tax | 46.88K | $1.66M |
| 2026-06-29 | Epperly Melissa B, | Option exercise | 17.75K | $79.17K | |
| 2026-06-29 | Epperly Melissa B, | Sell | 15.00K | $514.87K | |
| 2026-06-29 | Epperly Melissa B, | Sell | 2.75K | $95.38K |
Flow & Concentration
| Insider 180d net | -$959.25K |
|---|---|
| Insider buys / sells | 0 / 3 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 99.5% |
| HHI | 4,337 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| Fidelity / FMR LLC | $2.87B | 81.02M |
| State Street Corp | $629.80M | 17.80M |
| Capital Research / Capital World | $618.14M | 17.47M |
| AQR Capital Management | $234.03M | 6.63M |
| Citadel Advisors | $205.73M | 5.81M |
| Millennium Management | $24.79M | 700.49K |
| T. Rowe Price Group | $170.47K | 4.82M |
As of 2026-06-30
SEC Filings
The Long Run
FY 2022–2024 · 3 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $31.53M | +15.1% | |
| Operating income | -$1.00B | — | |
| Net income | -$171.98M | — | |
| Cash from ops | -$765.27M | — |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $35.98 | $36.19 | $35.51 | $35.80 | 6.76M |
| Sep 24 | $36.64 | $36.75 | $35.90 | $36.13 | 5.66M |
| Sep 23 | $38.00 | $38.47 | $36.78 | $36.82 | 9.27M |
| Sep 22 | $38.73 | $39.17 | $38.11 | $38.22 | 6.75M |
| Sep 21 | $39.02 | $39.90 | $38.72 | $38.99 | 5.62M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →